EPS5.01 Change in gut microbiota following elexacaftor/tezacaftor/ivacaftor (ETI) therapy: preliminary analysis

Objectives: Abnormal cystic fibrosis transmembrane conductance regulator (CFTR) function is associated with gut dysbiosis in people with cystic fibrosis. The recently introduced elexacaftor/tezacaftor/ivacaftor (ETI) therapy has proved highly effective at improving clinical status, reducing pulmonary exacerbations and increasing weight. There is presently little data on the impact of ETI on CF-related gut dysbiosis. In this study, we explored compositional changes of the gut microbiota following ETI therapy.